Anti-neoplastic chemotherapy can determine various side effects, including cardiotoxicity, and no real guidelines for its early detection and management have been developed. The aim of this study is to find some plasmatic markers able to identify breast cancer patients that are at greater risk of developing cardiovascular complications during chemotherapy, in particular heart failure. A prospective study on 100 breast cancer patients with mean age of 66 years in adjuvant treatment with anthracyclines, taxanes, and trastuzumab was performed. Patients underwent cardiological examination before starting treatment (T0) and at 3 months (T1), 6 months (T2), and 1 year (T3) after treatment. Evaluation of serum cardiac markers and N-terminal pro-brain natriuretic peptide (NT-proBNP) was performed at T0, T1, T2, and T3, simultaneously to electrocardiogram and echocardiogram, showing a significant increase in NT-proBNP concentration (p > 0.0001) at T1, T2, and T3, before left ventricular ejection fraction decrease became evident. Human epidermal growth factor receptor 2 (HER2)-negative patients were more susceptible to mild hematological cardiotoxicity, while HER2-positive patients were more susceptible to severe cardiotoxicity. A significant correlation between NT-proBNP increased values after chemotherapy and prediction of mortality at 1 year was evidenced. From our experience, serum biomarker detection was able to support an early diagnosis of cardiac damage, also in the absence of left ventricular ejection fraction decrease. Therefore, the evaluation of specific plasmatic markers for cardiac damage is more sensitive than echocardiography in the early diagnosis of chemotherapy-related cardiotoxicity; furthermore, it can also add a prognostic value on outcome.

Serum biomarkers evaluation to predict chemotherapy-induced cardiotoxicity in breast cancer patients / DE IULIIS, Francesca; Salerno, Gerardo; Taglieri, Ludovica; DE BIASE, Luciano; Lanza, Rosina; Cardelli, Patrizia; Scarpa, Susanna. - In: TUMOR BIOLOGY. - ISSN 1010-4283. - STAMPA. - 37:3(2016), pp. 3379-3387. [10.1007/s13277-015-4183-7]

Serum biomarkers evaluation to predict chemotherapy-induced cardiotoxicity in breast cancer patients

DE IULIIS, FRANCESCA;Salerno, Gerardo;Taglieri, Ludovica;DE BIASE, Luciano;CARDELLI, Patrizia;SCARPA, Susanna
2016

Abstract

Anti-neoplastic chemotherapy can determine various side effects, including cardiotoxicity, and no real guidelines for its early detection and management have been developed. The aim of this study is to find some plasmatic markers able to identify breast cancer patients that are at greater risk of developing cardiovascular complications during chemotherapy, in particular heart failure. A prospective study on 100 breast cancer patients with mean age of 66 years in adjuvant treatment with anthracyclines, taxanes, and trastuzumab was performed. Patients underwent cardiological examination before starting treatment (T0) and at 3 months (T1), 6 months (T2), and 1 year (T3) after treatment. Evaluation of serum cardiac markers and N-terminal pro-brain natriuretic peptide (NT-proBNP) was performed at T0, T1, T2, and T3, simultaneously to electrocardiogram and echocardiogram, showing a significant increase in NT-proBNP concentration (p > 0.0001) at T1, T2, and T3, before left ventricular ejection fraction decrease became evident. Human epidermal growth factor receptor 2 (HER2)-negative patients were more susceptible to mild hematological cardiotoxicity, while HER2-positive patients were more susceptible to severe cardiotoxicity. A significant correlation between NT-proBNP increased values after chemotherapy and prediction of mortality at 1 year was evidenced. From our experience, serum biomarker detection was able to support an early diagnosis of cardiac damage, also in the absence of left ventricular ejection fraction decrease. Therefore, the evaluation of specific plasmatic markers for cardiac damage is more sensitive than echocardiography in the early diagnosis of chemotherapy-related cardiotoxicity; furthermore, it can also add a prognostic value on outcome.
2016
anthracicline; breast cancer; cardiotoxicity; chemotherapy; taxanes; trastuzumab; cancer research
01 Pubblicazione su rivista::01a Articolo in rivista
Serum biomarkers evaluation to predict chemotherapy-induced cardiotoxicity in breast cancer patients / DE IULIIS, Francesca; Salerno, Gerardo; Taglieri, Ludovica; DE BIASE, Luciano; Lanza, Rosina; Cardelli, Patrizia; Scarpa, Susanna. - In: TUMOR BIOLOGY. - ISSN 1010-4283. - STAMPA. - 37:3(2016), pp. 3379-3387. [10.1007/s13277-015-4183-7]
File allegati a questo prodotto
File Dimensione Formato  
Scarpa_serum_2016.pdf

solo gestori archivio

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 1.01 MB
Formato Adobe PDF
1.01 MB Adobe PDF   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/868421
Citazioni
  • ???jsp.display-item.citation.pmc??? 21
  • Scopus 50
  • ???jsp.display-item.citation.isi??? 45
social impact